Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) announced that the Company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a continuation of the patent entitled “Sensitive Immunochromatographic Assay”. This patent covers key aspects of Response Biomedical’s lateral flow immunoassays with the proprietary RAMP® testing platform.
Dr. Paul Harris, Vice President, Research and Development stated, “The continuation for the competitive claims significantly expands our U.S. intellectual property to allow coverage of assays for small molecules. This opens up whole new major markets in the areas of Therapeutic Drug Monitoring, Drugs of Abuse and other markets. We will be looking intently into potential new partnerships to explore this opportunity.”
The Fong Patent describes various methods to improve performance and correct intrinsic variability in lateral flow assays, providing more precise results than other lateral flow methods. The original Fong Patent has been issued in the United States and Australia and is pending in the European Union, China, Hong Kong, Japan and Canada.
Research demonstrates a bat species' resistance to cancer, pinpoints key genes